Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

52.41 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,130,071
Open 52.41
Bid (Size) 53.87 (29)
Ask (Size) 53.90 (5)
Prev. Close 52.41
Today's Range 52.41 - 52.41
52wk Range 45.05 - 139.74
Shares Outstanding N/A
Dividend Yield 4.19%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Weight-Loss Drugmaker Novo Nordisk’s Stock Is Rising Premarket Today
Via Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
From Pomerantz LLP
Via GlobeNewswire

Performance

YTD
-40.1%
-40.1%
1 Month
-18.5%
-18.5%
3 Month
-21.8%
-21.8%
6 Month
-36.3%
-36.3%
1 Year
-61.2%
-61.2%

More News

Read More
1 Stock Down 40% This Year to Buy and Hold
Via The Motley Fool
This Healthcare Stock's Bad News Could Create a $10 Billion Opportunity for Competitors
Via The Motley Fool
Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet.
Via The Motley Fool
Topics Economy
Why Novo Nordisk Flew Almost 3% Higher on Friday
Via The Motley Fool
Topics Government
Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO
Via NewMediaWire
Topics Fraud Lawsuit
Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease
Via Benzinga
Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst
Via Benzinga
This House of Representative Just Bought Up To $95K In Novo Nordisk Stock
Via Benzinga
Eli Lilly Strikes $1.3 Billion Deal With Superluminal To Develop AI-Driven Obesity Drugs
Via Benzinga
Topics Artificial Intelligence
Robbins LLP Urges NVO Stockholders with Large Losses to Contact the Firm for Information about Leading the Class Action Against Novo Nordisk A/S
From Robbins LLP
Via GlobeNewswire
Eli Lilly To Raise Mounjaro Price In UK, Expands Obesity Drug Push In India
Via Benzinga
3 Absurdly Cheap Stocks That Haven't Been Trading This Low in Years
Via The Motley Fool
Topics World Trade
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Nordisk A/S Lawsuit - NVO
Via NewMediaWire
Topics Fraud Lawsuit
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 30, 2025 in Novo Nordisk A/S Lawsuit - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
Best Stock to Buy: Novo Nordisk Stock vs. UnitedHealth Stock
Via The Motley Fool
Why Novo Nordisk Stock Topped the Market Today
Via The Motley Fool
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
From The Rosen Law Firm PA
Via GlobeNewswire
Why Eli Lilly Stock Popped Today
Via The Motley Fool
Weighing The Costs: Obesity Drug Users Make Financial Sacrifices As Coverage Tightens
Via Benzinga
How Novo Nordisk's Weight-Loss Drug Could Unlock A Better Future For Biogen's Alzheimer's Treatment
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines – NVO
From Pomerantz LLP
Via GlobeNewswire

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 52.41
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 08/15/25 07:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.